Comparison of HIV Virologic Failure Rates between Patients with Variable Adherence to Three Antiretroviral Regimen Types

AIDS Patient Care and STDs

Volumn 29, Issue 7, 2015, Pages 384-388

  Gordon, Lindsay L ^a   Gharibian, Derenik ^a   Chong, Karen ^a   Chun, Helen ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RALTEGRAVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GOLD STANDARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NONHUMAN; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; VIRUS INHIBITION; VIRUS LOAD; ADOLESCENT; AGED; ANTIVIRAL RESISTANCE; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; TREATMENT FAILURE; UNITED STATES; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALIFORNIA; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 84934290673     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2014.0165     Document Type: Article

References (19)

1. May M, Gompels M, Sabin C. Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK Collaborative HIV Cohort Study. J Int AIDS Soc 2012;15.
2. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-1183.
3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
4. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007;45:4-8.
5. Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008;61:769-773.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services,. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. Guidelines]. May 1, 2014; http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (Last accessed May 20, 2014).
7. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387-402.
8. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005;40:158-163.
9. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-941.
10. Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother 2011;45:372-379.
11. Saberi P, Caswell N, Amodio-Groton M, Alpert P. Pharmacyrefill measure of adherence to efavirenz can predict maintenance of HIV viral suppression. AIDS Care 2008;20:741-745.
12. Cocohoba JM, Murphy P, Pietrandoni G, Guglielmo BJ. Improved antiretroviral refill adherence in HIV-focused community pharmacies. J Am Pharm Assoc (2003) 2012;52:e67-e73.
13. McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: Review of the literature and implications for treatment monitoring. Clin Infect Dis 2011;52:493-506.
14. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-116.
15. Genberg BL, Lee Y, Rogers WH, Willey C, Wilson IB. Stages of change for adherence to antiretroviral medications. AIDS Patient Care STDS 2013;27:567-572.
16. Babson KA, Heinz AJ, Bonn-Miller MO. HIV medication adherence and HIV symptom severity: The roles of sleep quality and memory. AIDS Patient Care STDS 2013;27:544-552.
17. Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One 2009;4:e7196.
18. Ammassari A, Trotta MP, Shalev N, Marconi P, Antinori A. Beyond virological suppression: The role of adherence in the late HAART era. Antivir Ther 2012;17:785-792.
19. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009;50:529-536.